1.
Br J Haematol
; 197(3): 302-305, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1714139
ABSTRACT
We have vaccinated 392 patients with two doses of mRNA COMIRNATY vaccine with an overall antibody response of 70% (best in cMPN, worst in CLL). We have then vaccinated 80 patients who did not achieve seroconversion or were low responders with a third dose of COMIRNATY vaccine. Our first results show promise, especially for patients on anti-CD38 therapy.